Overview
VTRS market data
Price History
VTRS price chart · 1M
- O
- 16.73
- H
- 17.10
- L
- 16.66
- C
- 16.92
- Vol
- 280,240.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $16.73
- Previous Close
- $16.86
- Day High
- $17.10
- Day Low
- $16.66
- 52 Week High
- $18.19
- 52 Week Low
- $14.49
- 7 Day Return
- +5.75%
- 30 Day Return
- -4.62%
- 90 Day Return
- +4.83%
- 1 Year Return
- +14.63%
- Daily Notional Volume
- $4.7M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$3.00 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.88 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 2.7% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -2.8% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $9.43 – $18.39 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $18.7B · P/B 0.97 · P/S 1.27.
Company News
Viatris shares are trading lower despite reporting better-than-expected Q2 financial results, possibly dragged down by wider GAAP net loss, near-term supply risks, and weakness in Emerging Markets.Benzinga · Aug 6, 2026, 6:55 PM
Viatris Sharpens Focus with Divestiture, Hikes 2026 OutlookBenzinga · Aug 6, 2026, 5:56 PM
8-K filing — Viatris Inc (VTRS)SEC EDGAR · Aug 6, 2026, 11:56 AM
Viatris Q2 Adj. EPS $0.69 Beats $0.60 Estimate, Sales $3.756B Beat $3.675B EstimateBenzinga · Aug 6, 2026, 11:07 AM
Viatris Raises FY2026 Adj EPS Guidance from $2.33-$2.47 to $2.45-$2.49 vs $2.44 Est; Raises FY2026 Sales Guidance from $14.450B-$14.950B to $14.550B-$14.950B vs $14.783B EstBenzinga · Aug 6, 2026, 11:00 AM
Viatris Receives EMA CHMP Recommendation For Approval Of Ruxolitinib Viatris For The Treatment Of Myelofibrosis, Polycythaemia Vera And Graft-Vs-Host DiseaseBenzinga · Jul 24, 2026, 10:35 AM
Shares of generic drug companies are trading lower after President Trump announced that imported generics will be subject to a 100% import tariff following a two-year grace period in order to encourage reshoring of pharma manufacturing.Benzinga · Jul 22, 2026, 4:27 PM
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend YieldsBenzinga · Jul 14, 2026, 11:30 AM
Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?The Motley Fool · Jul 9, 2026, 5:15 PM
Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?The Motley Fool · Jul 6, 2026, 6:15 PM